We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
Read MoreHide Full Article
Gilead Sciences, Inc. (GILD - Free Report) announced positive top-line results from yet another late-stage study on breast cancer drug, Trodelvy (sacituzumab govitecan-hziy).
Data from the phase III ASCENT-03 study on Trodelvy showed highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for checkpoint inhibitors.
This is the second positive phase III study in first-line mTNBC where Trodelvy has demonstrated a clinically meaningful benefit versus standard of care chemotherapy.
Gilead’s shares have surged 17.1% year to date against the industry's decline of 5%.
Image Source: Zacks Investment Research
More on GILD’s Trodelvy
Trodelvy is a first-in-class Trop-2-directed antibody-drug conjugate.
The ASCENT-03 study is a global, open-label, randomized phase III trial evaluating the efficacy and safety of Trodelvy compared with treatment of physician’s choice in patients with previously untreated, locally advanced, inoperable mTNBC whose tumors do not express PD-L1, or who are PD-L1 positive and previously treated with a PD-(L)1 inhibitor in the curative setting.
Approximately 540 patients were enrolled across multiple study sites worldwide.
These patients were randomized equally to receive either Trodelvy (10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle) or treatment of the physician’s choice, which included gemcitabine plus carboplatin, paclitaxel, or nab-paclitaxel.
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in PFS compared to chemotherapy in first-line mTNBC patients.
The safety profile of Trodelvy in the ASCENT-03 study was consistent with the prior studies.
Overall survival (OS) is a key secondary endpoint. The OS data was not mature at the time of PFS primary analysis. Hence, Gilead will continue to monitor OS outcomes, with ongoing patient follow-up and further analysis planned.
Please note that Trodelvy is currently approved in more than 50 countries for second-line or later mTNBC patients and in several countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer.
Last month, Gilead announced positive top-line results from the phase III ASCENT-04/KEYNOTE-D19 study. Data showed Trodelvy plus Merck’s (MRK - Free Report) blockbuster drug Keytruda (pembrolizumab) significantly improved PFS compared to Keytruda and chemotherapy in patients with inoperable (unresectable) locally advanced or mTNBC whose tumors express PD-L1. This study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in PFS.
Per GILD, positive data from the ASCENT-03 and ASCENT-04 study demonstrate Trodelvy’s potential as the backbone treatment for all patients across first-line mTNBC.
Gilead has additional ongoing phase III studies evaluating Trodelvy across HER2 breast cancer, including the ASCENT-07 pivotal trial in patients with HR+/HER2- mBC who have received endocrine therapy, and the ASCENT-05 pivotal trial in patients with early-stage TNBC (eTNBC). The drug is also being evaluated in additional late-stage studies across a range of tumor types, including lung and gynecologic cancers.
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead’s oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds in the United States and Europe that are expected to continue in 2025.
The potential launch of anito-cel in multiple myeloma and Trodelvy in first-line metastatic triple-negative breast cancer in 2026 will strengthen the company’s oncology business.
GILD is one of the dominant players in the HIV market. Gilead’s efforts to constantly innovate its HIV portfolio should enable it to maintain growth amid competition from GSK plc.
The company’s pipeline candidate, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women. The FDA accepted new drug application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a target action date of June 19, 2025.
GILD has also collaborated with Merck to evaluate the investigational combination of islatravir and lenacapavir for the treatment of HIV. The potential launch of lenacapavir for PrEP in 2025 will be a significant boost for the company.
The Zacks Consensus Estimate Novartis’ 2025 earnings per share (EPS) has risen from $8.47 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 20 cents to $9.02 during this timeframe. The stock has risen 18.6% so far this year.
Pfizer’s 2025 EPS estimate has risen from $2.97 to $3.06 in the past 60 days, while that for 2026 has gone up from $2.99 to $3.09 over the same timeframe.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
Gilead Sciences, Inc. (GILD - Free Report) announced positive top-line results from yet another late-stage study on breast cancer drug, Trodelvy (sacituzumab govitecan-hziy).
Data from the phase III ASCENT-03 study on Trodelvy showed highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for checkpoint inhibitors.
This is the second positive phase III study in first-line mTNBC where Trodelvy has demonstrated a clinically meaningful benefit versus standard of care chemotherapy.
Gilead’s shares have surged 17.1% year to date against the industry's decline of 5%.
Image Source: Zacks Investment Research
More on GILD’s Trodelvy
Trodelvy is a first-in-class Trop-2-directed antibody-drug conjugate.
The ASCENT-03 study is a global, open-label, randomized phase III trial evaluating the efficacy and safety of Trodelvy compared with treatment of physician’s choice in patients with previously untreated, locally advanced, inoperable mTNBC whose tumors do not express PD-L1, or who are PD-L1 positive and previously treated with a PD-(L)1 inhibitor in the curative setting.
Approximately 540 patients were enrolled across multiple study sites worldwide.
These patients were randomized equally to receive either Trodelvy (10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle) or treatment of the physician’s choice, which included gemcitabine plus carboplatin, paclitaxel, or nab-paclitaxel.
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in PFS compared to chemotherapy in first-line mTNBC patients.
The safety profile of Trodelvy in the ASCENT-03 study was consistent with the prior studies.
Overall survival (OS) is a key secondary endpoint. The OS data was not mature at the time of PFS primary analysis. Hence, Gilead will continue to monitor OS outcomes, with ongoing patient follow-up and further analysis planned.
Please note that Trodelvy is currently approved in more than 50 countries for second-line or later mTNBC patients and in several countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer.
Last month, Gilead announced positive top-line results from the phase III ASCENT-04/KEYNOTE-D19 study. Data showed Trodelvy plus Merck’s (MRK - Free Report) blockbuster drug Keytruda (pembrolizumab) significantly improved PFS compared to Keytruda and chemotherapy in patients with inoperable (unresectable) locally advanced or mTNBC whose tumors express PD-L1. This study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in PFS.
Per GILD, positive data from the ASCENT-03 and ASCENT-04 study demonstrate Trodelvy’s potential as the backbone treatment for all patients across first-line mTNBC.
Gilead has additional ongoing phase III studies evaluating Trodelvy across HER2 breast cancer, including the ASCENT-07 pivotal trial in patients with HR+/HER2- mBC who have received endocrine therapy, and the ASCENT-05 pivotal trial in patients with early-stage TNBC (eTNBC). The drug is also being evaluated in additional late-stage studies across a range of tumor types, including lung and gynecologic cancers.
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead Sciences, Inc. price-consensus-eps-surprise-chart | Gilead Sciences, Inc. Quote
GILD Looking to Diversify Portfolio
Gilead’s oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds in the United States and Europe that are expected to continue in 2025.
The potential launch of anito-cel in multiple myeloma and Trodelvy in first-line metastatic triple-negative breast cancer in 2026 will strengthen the company’s oncology business.
GILD is one of the dominant players in the HIV market. Gilead’s efforts to constantly innovate its HIV portfolio should enable it to maintain growth amid competition from GSK plc.
The company’s pipeline candidate, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women. The FDA accepted new drug application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a target action date of June 19, 2025.
GILD has also collaborated with Merck to evaluate the investigational combination of islatravir and lenacapavir for the treatment of HIV. The potential launch of lenacapavir for PrEP in 2025 will be a significant boost for the company.
GILD’s Zacks Rank and Stocks to Consider
Gilead currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis (NVS - Free Report) and Pfizer (PFE - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate Novartis’ 2025 earnings per share (EPS) has risen from $8.47 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 20 cents to $9.02 during this timeframe. The stock has risen 18.6% so far this year.
Pfizer’s 2025 EPS estimate has risen from $2.97 to $3.06 in the past 60 days, while that for 2026 has gone up from $2.99 to $3.09 over the same timeframe.